Revenue revised downward to 821 million yen (previous forecast: 943 million yen). Operating income: -1,520 million yen; Ordinary income: -1,360 million yen; Net income: -1,426 million yen. Revenue is down 12.9% versus the same period last year. Revision reasons include decreased sales of S-DSC and delays in offering new menus, and increased R&D expenses related to Stempeucel.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2370","jir_company_name":"MEDINET Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2370-20261016-01.pdf","jir_short_summary":"Revenue revised downward to 821 million yen (previous forecast: 943 million yen). Operating income: -1,520 million yen; Ordinary income: -1,360 million yen; Net income: -1,426 million yen. Revenue is down 12.9% versus the same period last year. Revision reasons include decreased sales of S-DSC and delays in offering new menus, and increased R&D expenses related to Stempeucel.","jir_summary":"### Summary of Revision to Earnings Guidance\nMEDINET Co., Ltd. has revised downward its full-year earnings guidance for the fiscal year ending September 2026. Revenue has been revised down by 121 million yen to 821 million yen from the previous forecast. The main factors include that, although the number of S-DSC-related specific cell processed product manufacturing cases exceeded the prior year, a decrease in overseas patient numbers in the immune cell field and delays in menu provision had an adverse impact. In the CDMO business, while technology transfer for manufacturing of clinical trial products was completed, some projects experienced delayed start times, resulting in postponed revenue recognition. On the profit side, despite reductions in general and administrative expenses, profit deterioration due to lower revenue and increased development expenses related to Stempeucel have combined, leading to revisions to operating income of -1,520 million yen, ordinary income of -1,360 million yen, and net income of -1,426 million yen.\n\n### Outlook and Impact\nRevenue declines and increased development expenses are expected to continue to suppress profits, and depending on project progress there is a possibility that project starts may be pushed into the fiscal year ending September 2027. Recovery of certain long-term loans and improvements in related operations are, however, expected to be modest positive factors for ordinary income.","jir_financial_highlights":"Revenue: 821 million yen (Revised from previous forecast of 943 million yen (decrease of 121 million yen) \/ -12.9%)\nOperating Income: -1,520 million yen (Decreased by 66 million yen from previous forecast)\nOrdinary Income: -1,360 million yen (Increased by 89 million yen from previous forecast)\nNet Income Attributable to Owners of Parent: -1,426 million yen (Increased by 27 million yen from previous forecast)\nNet Income per Share: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ShareBuyback, #ExecutivePersonnel","jir_key_figures":"Revenue: 821 million yen\nOperating Income: -1,520 million yen\nOrdinary Income: -1,360 million yen","jir_meta_title":"MEDINET Co., Ltd. Revises Earnings Guidance Downward | Revenue 821 million yen, Operating Income -1,520 million yen","jir_meta_description":"MEDINET Co., Ltd. has revised its full-year earnings guidance for the fiscal year ending September 2026. Revenue is 821 million yen and operating income is -1,520 million yen. Reasons include trends in S-DSC-related cases and increased Stempeucel-related expenses. Details and year-over-year comparisons explained.","jir_og_title":"MEDINET Co., Ltd. Revises Earnings Guidance Downward | Revenue 821 million yen","jir_og_description":"MEDINET Co., Ltd. has revised its full-year earnings guidance for the fiscal year ending September 2026. Explanations of factors and outlook for revenue of 821 million yen and operating income of -1,520 million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":122814,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-132186","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n